# Tolera Bio — Company Brand Brief
### *Teaching the immune system to forget the foods that harm it.*

*Founder: Ruth-Anne Pai, PhD — immunologist and person living with eosinophilic esophagitis (EoE)*
*Confidential — for VC / VP discussion. Founding brief, v1.*

---

## 1. Company name

**Recommended: Tolera Bio** (working legal name *Tolera Biosciences, Inc.*)

**Pronunciation:** Tolera /ˈtoʊ.lɛr.ə/ — "TOE-lair-uh" (stress the middle syllable; echoes *tolerance*).

From *tolerance* — the immunological state the platform induces, and the one word that separates this company from every approved and pipeline EoE drug. Short, pronounceable, ownable, and it says the mechanism out loud. "Tolera" reads as a verb-like coinage ("to tolerate"), which lets the brand carry the thesis without a tagline.

### Alternatives considered
| Name | Rationale | Why not #1 |
|---|---|---|
| **Tolera Bio** ✓ | *Tolerance* as the noun that defines the category; mechanism-forward | — (recommended) |
| **Anergx** | From *anergy* (Signal-1 T-cell silencing) + "-gx" gene/therapeutic suffix | Too jargon-inward; "anergy" is unknown outside immunology, harder for generalist VCs |
| **Reclaira** (from *re-claim* / re-educate) | Emotional, patient-facing; "reclaim the foods you lost" | Evokes benefit, not mechanism; weaker scientific credibility to a technical DD team |

**Tagline (locked):** *Antigen-specific tolerance, one patient at a time.*
**Alt patient-facing tagline:** *Teaching the immune system to forget the foods that harm it.*

---

## 2. Mission

To make **durable, antigen-specific tolerance** the standard of care for food-driven immune disease — beginning with eosinophilic esophagitis — so that a patient's own biopsy and blood become the blueprint for a personalized vaccine that retires the offending T-cell clone instead of suppressing the whole immune system for life.

---

## 3. Founding thesis

Four claims that, taken together, define why Tolera Bio should exist and why now:

1. **EoE is antigen-specific, but every therapy is not.** The disease is driven by a specific food **peptide, presented on a specific MHC-II molecule, to a specific pathogenic effector-Th2 (peTH2) TCR** — a defined pMHC–TCR triad (Dilollo/Spergel/Hill 2025 functionally validated the first such TCR, eoeTCR-4). Yet every approved drug (dupilumab, budesonide) and every pipeline agent (cendakimab, tezepelumab) blocks a *downstream cytokine or cell* and must be taken **indefinitely**. None touches the antigen-specific cause.

2. **Tolerance induction is de-risked in principle.** Teplizumab (anti-CD3, *Tzield*) proved the FDA will approve an immune-modifying agent that changes disease trajectory rather than palliating symptoms. Individualized neoantigen cancer vaccines (mRNA-4157, autogene cevumeran) proved that a **per-patient manufactured biologic** can clear regulatory and CMC hurdles. Tolera does for a *self-food antigen* what those did for tumor neoantigens.

3. **The design already exists and computes.** This is not a slide-ware concept. A 9-construct pMHC-II panel on a shared HLA-DRB1*07:01 backbone has been designed and GPU-validated (ipTM ≥ 0.87, full 15-residue groove engagement), anchored on the one tetramer-validated EoE food epitope (β-casein aa59–78). The companion blood-based food-trigger diagnostic is specified.

4. **The founder is the patient.** Tolera is built by an immunologist who lives with EoE. That is not a marketing note — it is a durable advantage in trial design, patient recruitment, community trust, and the moral clarity of the mission.

---

## 4. Positioning statement

> **For** the ~160,000 diagnosed EoE patients in the US who face a lifetime of steroids, biologics, or restrictive elimination diets, **Tolera Bio** is a **personalized tolerance-vaccine company** that **retires the food-reactive T-cell clone driving their disease** from a single biopsy and blood draw. **Unlike** dupilumab, cendakimab, or budesonide — chronic-dosing symptom suppressors that work only while taken — **Tolera** induces **durable, antigen-specific tolerance**, aiming for a one-course intervention rather than lifelong therapy.

**Category we are creating:** *antigen-specific tolerance therapeutics* — the immunology mirror-image of individualized neoantigen vaccines in oncology.

---

## 5. Positioning axes (the whitespace)

Every competitor clusters in one quadrant; Tolera owns the opposite corner:

- **X-axis — Mechanism:** broad immunosuppression ⟶ antigen-specific
- **Y-axis — Durability:** chronic dosing ⟶ durable / one-course tolerance

PPIs, steroids (budesonide/Eohilia), and the biologics (dupilumab, cendakimab, tezepelumab) all sit **broad + chronic**. Tolera sits alone at **antigen-specific + durable**.

---

## 6. Visual identity concept

- **Motif:** the MHC-II groove cradling a peptide — abstracted to a single open "cradle" arc holding a small shape. Signals *presentation* and *holding/tolerance* at once.
- **Palette:**
  - `Tolera Teal #1F7A8C` — primary; calm, clinical, trustworthy (not the overused biotech royal-blue)
  - `Immune Coral #E86A5C` — accent; the "offending antigen" / the human warmth of the patient story
  - `Graphite #2B2D33` — text
  - `Mist #F2F4F5` — background
  - `Tolerance Sage #6DA67A` — the "resolved / tolerized" state in mechanism figures
- **Type:** a humanist sans (e.g. Source Sans / Inter) — scientific but not cold.
- **Tone of voice:** precise, honest about what is validated vs. computational, patient-centered without being saccharine. We never overclaim; the science is strong enough to state plainly.

---

## 7. What we are NOT

- Not another anti-cytokine biologic.
- Not broad immunosuppression.
- Not a lifelong-dosing chronic-therapy business.
- Not claiming clinical validation we don't have — the dairy anchor is tetramer-validated; wheat/soy and all binding values are computational priors pending wet-lab confirmation.